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OBJECTIVES: Warfarin had been the only effective oral anticoagulant (OAC) to 
reduce risk of ischemic stroke in patients with atrial fibrillation (AF) until 
recently new OACs (dabigatran, rivaroxaban and apixaban) became possible 
alternatives for AF patients. Cost-effectiveness of new OACs versus warfarin 
therapy in AF patients was examined. METHODS: A Markov model was designed 
to compare life-long economic and treatment outcomes of apixaban (5mg twice 
daily), dabigatran (150mg twice daily), rivaroxaban (20mg daily), and warfarin 
therapy at anticoagulation care with moderate control on anticoagulation (mean 
time in therapeutic range (TTR) 60.6%) in a hypothetical cohort of AF patients 
aged 65 years old with CHADS2 score 2. Model inputs were derived from 
literature, and outcome measure was incremental cost per quality-adjusted life-
year (QALY) gained (ICER) from the health care provider’s perspective. 
Robustness of model was examined by sensitivity analysis. RESULTS: In the 
base-case scenario, warfarin was the least costly alternative (USD82,768) and it 
gained lowest QALYs (9.571). ICERs of dabigatran and apixaban were USD38,382 
and USD204,787, respectively. Rivaroxaban was more costly and gained less 
QALYs than dabigatran and apixaban. Using USD50,000 as the threshold of 
willingness-to-pay per QALY, dabigatran was the most cost-effective option. The 
most influential factors on the base-case results were the risk of bleeding and 
ischemic stroke of dabigatran comparing to warfarin therapy. In 10,000 Monte 
Carlo simulations, dabigatran was the most likely option to be cost-effective in 
81% of time. CONCLUSIONS: In the present model, the ICER of dabigatran was 
acceptable as the cost-effective alternative when compared to the other new 
OACs and anticoagulation service with moderate anticoagulation control.  
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OBJECTIVES: Estimate the lifetime costs and life-years (LYs) gained associated 
with stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) 
using novel oral anticoagulants (NOACs) apixaban 5 mg, dabigatran 150 mg, and 
rivaroxaban 20 mg relative to warfarin. METHODS: A probabilistic Markov 
decision-analysis model was constructed to evaluate lifetime costs and LYs 
gained for patients receiving NOACs compared to patients receiving adjusted-
dose warfarin. The modeled population was a hypothetical cohort of 70-year old 
patients with NVAF, at an increased risk for stroke (CHADS2≥1), with a renal 
creatinine clearance ≥ 50 mL/min, and no prior contraindications to 
anticoagulation. Rates for clinical events associated with drug efficacy and safety 
were estimated from the RE-LY (dabigatran 150 mg twice daily), ARISTOTLE 
(apixaban 5 mg twice daily), and ROCKET-AF (rivaroxaban 20 mg once daily) 
clinical trials. Medical costs were estimated from a societal perspective and were 
inflated to 2012 US dollars. Sensitivity analyses were conducted to determine 
influential model variables. RESULTS: In the base case, warfarin had the lowest 
cost of $77,843 (standard deviation [SD]: $2,249), followed by rivaroxaban 20 mg 
($78,683±$1,801), dabigatran 150 mg ($82,719±$1,905), and apixaban 5 mg 
($85,350±$1,501). In contrast, warfarin had the highest estimated indirect costs 
($25,485±$58), whereas the estimates were similar for apixaban ($9,499±$6), 
dabigatran ($9,497±$7), and rivaroxaban ($9,514±$6). Apixaban 5 mg yielded the 
highest number of LY’s gained, 13.76 (SD: 0.09), followed by dabigatran 150 mg 
(13.73±0.10), rivaroxaban 20 mg (13.48±0.10), and warfarin (12.98±0.06). The 
model results were dependent upon treatment costs and neurologic events 
associated with rivaroxaban 20 mg. CONCLUSIONS: In patients with NVAF, 
apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg were more costly 
alternatives to warfarin but appear to result in a higher number of LYs gained.  
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OBJECTIVES: Resistant hypertension is a difficult condition to treat. More than 
5,000 patients with resistant hypertension have undergone surgery catheter 
based renal denervation (RDN) with good results. The primary objective of this 
study was to estimate the cost-effectiveness of catheter based renal denervation 
(RDN) for resistant arterial hypertension compared with standard of care (SC) in 
Colombia. METHODS: Using a previously validated excel-based Markov model, 
we projected the lifetime effect of RDN or standard of care in direct medical costs 
and outcomes. The model considered 6 health states: stroke, myocardial 
infarction, heart failure, end-stage renal disease, angina and death; The relative 
risk associated with RDN compared to SC for stroke (0.77), Myocardial infarction 
(0.74-0.90), Heart Failure (0.73) and end-stage renal disease (0.87) were extracted 
from the literature and converted into transition probabilities. Costs for drugs, 
procedures and other health care resources were obtained from local sources, 
and private and official databases. Life expectancy data was imputed from the 
WHO’s life tables and the utilities for each health state were derived from the 
literature. The analysis was performed using the payer perspective and used an 
annual discount for cost and outcomes of 3%. RESULTS: In our simulation, 
subjects undergoing RDN achieved higher QALY’s (10.27 vs. 9.72) at a higher cost 
during their lifetime (COP$91.406.781 vs. COP$80.799.285). The main drivers for 
these differences were the reduction in complications in the group of subject 
treated with RDN and the costs of treatment. These differences yielded and ICER 
of COP$19.301.843. CONCLUSIONS: Catheter based RDN compared with standard 
care appears to be a favorable strategy for resistant arterial hypertension in 
Colombia, resulting in lower cardiovascular morbidity and mortality and 
decreased renal complications.  
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OBJECTIVES: Atrial Fibrillation (AF) is the most common sustained cardiac 
arrhythmia affecting approximately 40,000 to 80,000 inhabitants in Costa Rica. 
AF increases stroke, thrombo-embolism, deaths, heart failure and 
hospitalizations rates, affecting the quality of life and raising overall costs. 
Literature suggests anticoagulation is the best strategy to prevent strokes and 
reduce death rates in AF. The aim of this study was to assess the cost-
effectiveness (CE) of warfarin against Apixaban, Rivaroxaban, and Dabigatran as 
therapy for AF, from the public health care perspective. METHODS: A simulated 
cohort of patients with AF entered a decision-tree model to compare costs and 
effectiveness of Warfarin (5 mg/day) (comparator), Apixaban (5 mg/12 hours), 
Dabigatran (110 mg/12 hours and 150 mg/12 hours), and Rivaroxaban (20 
mg/day). Effectiveness measures were: stroke, bleeding and myocardial 
infarction (MI) rates and deaths. The model used a lifetime horizon and only 
direct medical costs were considered (inpatient costs, medication expenses, 
adverse events costs, tests). Effectiveness and epidemiologic data were retrieved 
from published literature. Local costs (US$ 2012) were gathered from the Social 
Security of Costa Rica official databases. RESULTS: Apixaban resulted as the less 
expensive option for AF in adult patients and it was the only treatment that 
consistently prevented all three considered diseases: Three MIs, 18 strokes, 54 
bleedings avoided when compared to Warfarin. Mortality rate was found to be 
similar with all strategies implemented. Overall costs were US$43,211,440.23 for 
warfarin, US$38,240,522.33 for Apixaban (lowest), US$38,458,665.03 for 
Dabigatran 110 mg, US$41,055,937.68 for Dabigatran 150 mg, and 
US$42,551,663.86 for Rivaroxaban. In the CE incremental analysis, Apixaban 
appeared as a cost-saving option. Apixaban obtained the highest probability of 
being cost-effective with a 3 GPB per capita in Costa Rica. PSA results support the 
robustness of these findings. CONCLUSIONS: Apixaban resulted as the cost-
saving therapy for AF adult patients in Costa Rica.  
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OBJECTIVES: The aim of the study was to demonstrate the cost effectiveness and 
cost utility of Ivabradine (Procoralan®) in the treatment of patients with Chronic 
Heart Failure (CHF) in Mexico, from the institutional perspective. METHODS: We 
used decision analysis to calculate the cost-effectiveness and cost utility of 2 
competing strategies in the treatment of patients with CHF using the results of 
SHIFT study: 1) Ivabradine plus standard care and 2) standard care. A Markov 
model was developed, the model considers two base case analyses; 29 months 
and extrapolated lifetime. The outcome measure was life years gained (LY) and 
quality adjusted life years (QALY), also incremental cost effectiveness ratio (ICER) 
was performed. Direct health care cost where used and the discount rate was of 
5%. The sensitivity analysis was carrying out in four time horizons: 29 months, 5 
years, 10 years and lifetime. Probabilistic sensitivity analysis was performed. 
RESULTS: Ivabradine plus standard care had more efficacy and less cost in the 
treatment of CHF. The incremental LY and QALY were 0.16 and 0.20, respectively 
on the 29 months analysis and 0.036 and 0.037, respectively for the lifetime 
horizon. The incremental cost using Ivabradine plus standard care was -$37,821 
in the 29 months’ time horizon, while in the lifetime horizon was -$53,710 for 
each LY and QALY. The sensitivity analyses proved that Ivabradine plus 
standard care was cost effective compared to standard care. According to the 
probabilistic sensitivity analyses, the likelihood of Ivabradine plus standard care 
to be cost effective is 100% under the willingness-to-pay threshold in Mexico. 
CONCLUSIONS: evidence from the clinical and the cost effectiveness study prove 
that the use of Ivabradine plus standard care in the treatment of patients with 
CHF is cost effective, and must be considered as first option in the treatment of 
patients with CHF diagnosis.  
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OBJECTIVES: In the Survival of Myocardial Infarction Long-term Evaluation 4 
Study (SMILE-4) zofenopril (Z) associated with acetylsalicylic acid (ASA) was 
superior to ramipril (R) plus ASA in reducing the occurrence of major 
cardiovascular events, in patients with left ventricular dysfunction (LVD) 
following acute myocardial infarction (AMI). The present post-hoc analysis was 
performed to evaluate cost-effectiveness of Z compared to R. METHODS: A total 
of 771 patients with LVD and AMI were randomized, double-blind to Z 60 mg/day 
(n=389) or R 10 mg/day (n=382) plus ASA 100 mg/day and followed-up for 1 year. 
The primary study end-point was 1-year combined occurrence of death or 
hospitalization for cardiovascular causes. The economic analysis was based on 
the evaluation of cost of medications and hospitalizations and was applied to the 
intention-to-treat population (n=716). Cost data were drawn from the database of 
the Italian National Health Service. The incremental cost-effectiveness ratio 
(ICER) was used to quantify the cost per event prevented with Z versus R. 
RESULTS: Z significantly (p=0.028) reduced the risk of the primary study end-
point by 30% as compared to ramipril (95% confidence interval: 49%, 4%). The 
number needed to treat to prevent a major cardiovascular event with Z was 13 
less than with R. The cost of drug therapies was higher with Z (€313.90 per 
patient per year, n=365) than with R (€160.60 per patient per year, n=351). The 
cost related to the occurrence of major cardiovascular events requiring 
hospitalization, averaged €3195.47 for Z and €3071.37 for R. The ICER of Z versus 
R was €1990.88 per event prevented. CONCLUSIONS: Z is a viable and cost-
effective treatment for managing patients with LVD after AMI.  
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OBJECTIVES: To demonstrate the cost-effectiveness (CE) of ticagrelor in the 
treatment of Acute Coronary Syndrome (ACS) in specific population: invasive, 
Unstable Angina (UA), ST-elevation myocardial infarction (STEMI), non-STEMI 
(NSTEMI), and with or without diabetes. METHODS: Analysis of 
ticagrelor+acetylsalicylic acid (ASA) and clopidogrel/ASA as fixed dose 
combination (FDC) was made using results of PLATO study and its sub-studies. A 
Markov model was developed to evaluate each specific population at a time 
horizon of 14 years from an institutional perspective in Mexico. Life years gained 
(LY) was the outcome measure. An incremental cost-effectiveness ratio (ICER) 
was performed. Direct health care costs were used and a 5% discount rate was 
applied. A Sensitivity Analysis (SA) and Cost Effectiveness Acceptability Curve 
(CEAC) were performed. RESULTS: The ICERs of Ticagrelor+ASA versus 
clopidogrel/ASA for each specific population were: $4,647 for UA; $4,024 for Non-
STEMI; $4,128 for STEMI; $4,607 for Invasive-treatment and $4,672 for population 
without Diabetes. The best results are shown in the Diabetes groups with ICER 
$3,011. The results of SA were consistent with the base case. The likelihood of 
Ticagrelor+ASA to be cost-effective is 100% under the willingness-to-pay 
threshold in Mexico of one PIB per-capita ($10,064). CONCLUSIONS: 
Ticagrelor+ASA was CE compared with clopidogrel/ASA in all specific groups, 
especially in diabetes and NSTEMI patients. Therefore it could be considered as 
the first option for treating these patients in an institutional setting.  
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OBJECTIVES: To conduct a systematic review of economic models of newer 
anticoagulants for stroke prevention in atrial fibrillation (SPAF). METHODS: We 
searched Medline, Embase, NHSEED and HTA databases and the Tuft’s Registry 
through October 10, 2012. Included models were cost-effectiveness analyses of 
newer agents for SPAF using a Markov or discrete event simulation model and 
published in English. RESULTS: Eighteen models were identified. Each was based 
on a lone randomized trial per new agent, and these trials were clinically and 
methodologically heterogeneous. Dabigatran 150mg, 110mg and sequential 
dosing were assessed in 9, 8, and 9 models, rivaroxaban in 4 and apixaban in 4. 
Warfarin was a first-line comparator in 94% of models. Models were conducted 
from the United States (44%), European countries (39%) and Canadian (17%) 
perspectives. In base-case analyses, patients typically were at moderate-risk of 
stroke, initiated anticoagulation at 65-73 years of age, and were followed for/near 
a lifetime. All models reported cost/quality-adjusted life-year, and while 22% 
reported using a societal perspective, no model included indirect costs. Four 
models reported an incremental cost-effectiveness ratio (ICER) for a newer 
anticoagulant (dabigatran 110mg (n=4)/150mg (n=2); rivaroxaban (n=1)) versus 
warfarin above commonly reported willingness-to-pay thresholds. ICERs 
(2012US$) versus warfarin ranged from $3,547-$86,000 for dabigatran 150mg, 
$20,713-$150,000 for dabigatran 110mg, $4,084-$21,466 for sequentially-dosed 
dabigatran and $23,065-$57,470 for rivaroxaban. Apixaban was demonstrated to 
be economically-dominant compared to aspirin, and dominant or cost-effective 
($11,400-$25,059) versus warfarin. Based on indirect comparisons, 3 models 
compared the cost-effectiveness of new agents and reported conflicting results. 
CONCLUSIONS: Cost-effectiveness models of newer anticoagulants for SPAF 
have been extensively published. They frequently found newer anticoagulants to 
be cost-effective, but due to the lack of head-to-head trials and the heterogeneity 
in clinical characteristic of underlying trials and modeling methods, it is 
currently unclear which of these newer agents is most cost-effective.  
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OBJECTIVES: To assess the clinical effectiveness and cost-effectiveness of renal 
denervation (RDN) in resistant hypertensive patients. METHODS: Two reviewers 
independently screened titles and abstracts for eligibility. Studies eligible for 
inclusion in the systematic review of cost-effectiveness were full cost-
effectiveness analyses, cost-utility analyses, cost-benefit analyses and cost-
consequence analyses. One reviewer performed data extraction, which was 
checked by two reviewers independently. Two reviewers independently applied 
quality assessment criteria and differences in opinion were resolved at each 
stage. Studies were synthesized through a narrative review with full tabulation 
of the results of all included studies. Robustness and uncertainty were evaluated 
using deterministic and probabilistic sensitivity analyses. RESULTS: RDN 
substantially reduced event probabilities. Median survival increased for RDN 
compared to standard of care. RDN was cost-effective in comparison to standard 
of care in the reviewed published estimates of cost-effectiveness. These 
estimates can not be directly extrapolated to other settings due to potential 
variations in cost structures and different treatment patterns among countries 
that may influence final results. Findings were relatively insensitive to variations 
in input parameters except for systolic blood pressure reduction, baseline 
systolic blood pressure, and effect duration. Renal denervation gave improved 
outcomes. CONCLUSIONS: RDN appears to be a clinically effective and cost-
effective intervention in resistant hypertensive patients compared with standard 
of care. Literature review suggests that RDN, over a wide range of assumptions, 
is a cost-effective strategy for resistant hypertension that might result in lower 
cardiovascular morbidity and mortality. Uncertainties remain and further 
research in Kazakhstan is required to provide detailed data on patient QoL and 
cost effectiveness in the local setting.  
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OBJECTIVES: To demonstrate the cost-effectiveness of rosuvastatin 5mg in the 
treatment of adult patients with hypercholesterolemia in Mexico, from the 
institutional perspective. METHODS: A Markov model was developed in three 
age groups: 45-55, 56-65 and 66-75, at two time horizons: 20 years and lifetime. 
Comparators were: atorvastatin 20mg, pravastatin 10mg and simvastatin 20mg. 
The measure of efficacy was based on the Blassetto; and STELLAR; studies, while 
patient characteristics were adapted to Mexican population. The outcome 
measure was life years gained (LY); direct health care costs were used and 
express in US dollars; a 5% discount rate was applied; the estimated mean costs 
and LY were calculated and the results were presented as Incremental cost-
effectiveness ratios (ICERs). Sensitivity analyses were performed. RESULTS: In 
lifetime and in 20 years horizon simvastatin and atorvastatin were dominated by 
rosuvastatin 5mg that had ICERs bellow the willingness-to-pay threshold in 
Mexico of 1 PIB per-capita ($10,064). The sensitivity analysis showed consistency. 
Incremental LY for rosuvastatin 5mg vs pravastatin 10mg were 0.281; 0.282 and 
0.234 for the 3 groups of age respectively. Incremental costs were $406.60; 
$251.87 and 101.72 with ICERs of $1,447.44; $893.00 and $434.72 respectively. 
CONCLUSIONS: Rosuvastatin 5mg showed extensive dominance over 
simvastatin and atorvastatin. It is also cost-effectiveness compared with 
pravastatin with ICERs below the wiliness-to-pay threshold of one PIB per capita. 
The use of rosuvastatin 5mg in the treatment of Mexican patients with 
hypercholesterolemia in different groups of age for 20 years and life time 
horizons is cost-effective, particularly in the 56-65 and 66-75 groups with very 
low ICERs.  
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OBJECTIVES: To evaluate the cost-effectiveness of rivaroxaban versus o 
enoxaparin+warfarin in the treatment of DVT. METHODS: A Markov model 
simulating the progression of DVT in the course of three month cycles, up to 
death, was adapted to Turkish setting. The health states included the events 
related with recurrent DVT and bleeding. The model provides the comparison of 
six-month treatment with rivaroxaban against enoxaparin+warfarin. Event rates 
and the treatment effects of rivaroxaban were derived from EINSTEIN DVT 
clinical trial. Time horizons studied were 5 years and life-time. Utility values 
were based on the published literature. Local 2012 prices were used as source of 
the costs. The incremental cost-effectiveness ratios (ICER) were calculated with 
life-years (LYs) and quality-adjusted LYs (QALYs) gained. One-way sensitivity 
analyses were undertaken to examine the effects of model drivers. The analysis 
was undertaken from a payer perspective. Discount rate was set at 3.5% for both 
costs and outcomes. Mid-2012 USD currency rate was used. Willingness-to-pay 
(WTP) threshold was set as twice the local gross domestic product per capita 
